Amanta Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amanta Healthcare Limited reported revenue from operations of Rs 28,767.67 lakhs for FY26, up 4.7% from Rs 27,470.82 lakhs in FY25. Profit after tax grew 41.7% to Rs 1,487.52 lakhs from Rs 1,050.07 lakhs. The company completed its IPO in September 2025, raising Rs 12,600 lakhs, with Rs 5,246.75 lakhs still unutilized as of March 2026. An exceptional item of Rs 262.88 lakhs was recognized for IPO-related listing expenses. Finance costs decreased significantly to Rs 2,074.57 lakhs from Rs 2,794.79 lakhs due to early redemption of non-convertible debentures. Cash and cash equivalents improved substantially to Rs 8,101.03 lakhs from Rs 22.06 lakhs. Capital work-in-progress increased sharply to Rs 8,151.77 lakhs from Rs 654.80 lakhs due to expansion projects at the Hariyala facility.
Strong PAT growth of 41.7% and successful IPO with doubled equity base are positives, but EBITDA margin compression to ~20.8% and heavy capital expenditure with substantial unutilized IPO proceeds warrant monitoring.